Covance worked on all of the top 50 best-selling drugs available today through its full spectrum of nonclinical, clinical and commercialization services.
Precision medicine in immuno-oncology
Great strides have been made in the discovery and validation of biomarkers in drug development.
Third Central Labs & Diagnostics Partnerships Forum
Find out how to solve key clinical trial challenges with actionable insights from specimen data.
Companion Diagnostics Case Study
End-to-end drug & diagnostic development support for a new immuno-oncology agent
Find out how Covance/LabCorp helped a prominent pharmaceutical company enable a faster, more effective launch of their immuno-oncology drug.
The diabetic heart: A focus on heart failure recording now available
Hear an insightful discussion on how certain molecular classes impact CV outcomes for patients with type 2 diabetes along with strategies for testing new therapeutic, paradigm-modifying treatment modalities.
Leverage new technological advances to accelerate HIV vaccine development
Read more about the challenges confronting the realization of an effective HIV-1 vaccine along with new solutions.
Virtual Clinic Tour
Take a look at our cGMP Pharmacy in Dallas
Game-changing control over Phase I drug manufacturing timelines and costs. Tour our Dallas Clinical Research Unit.
Solutions to minimize risk and optimize your trial designs
Discover how our innovation, commitment and expertise can accelerate your complex immuno-oncology drug development
New FDA labeling regulations are here
The new label is intended to better inform consumers about their choices.
Companion Diagnostics Event
Develop your biomarker strategy beyond oncology at World CDx Europe 2017
Join Tom Turi, Covance VP, Companion Diagnostics, as he presents on CDx uses in non-oncology therapeutic areas. Come early for a half-day workshop, hosted by Covance, on improving CDx development with clinical trial design. Learn more.
What matters to investigators
Recent study shows lab preferences make a difference in trial participation.
SpecimINSIGHTTM Case Study
Actionable consent data leads to no-go decision in five days before initiating costly Phase III trials, saving client an estimated $100M.
When a potentially market-limiting severe adverse reaction appeared in Phase I and II trials for an early stage Alzheimer’s disease drug development program, the client was able to quickly ensure consent for additional testing to properly determine genetic association. This actionable insight also prompted the client to discontinue trials on the initial compound and pivot to a backup compound.
Rare Disease and Orphan Drugs
Webinar: accelerate complex studies across the globe
A range of individual approaches can be integrated to accelerate your progress of complex rare disease studies across the world. Learn how to address key development challenges.
Assessing drug abuse liability
Key considerations – from early initiation to regulatory and market access – to effectively understand and adapt to the changing landscape of abuse potential.
Together with our clients, Covance is your CRO solution that transforms potential into reality.
We’re the world’s most comprehensive CRO, dedicated to advancing healthcare and delivering Solutions Made Real®
With precision delivery of the largest volume of drug development data on the planet, we can help you identify new approaches and anticipate tomorrow’s challenges.